Search for: All records

Photonic crystals are used to amplify the fluorescence emission and collection efficiency from quantum dots and plasmonic fluor nanoparticles to enable miRNA and proteins to be detected from plasma with single molecule precision, with simple 1-step assays. 

DNA has shown great biocompatibility, programmable mechanical properties, and precise structural addressability at the nanometer scale, rendering it a material for constructing versatile nanorobots for biomedical applications. Here, we present the design principle, synthesis, and characterization of a DNA nanorobotic hand, called DNA NanoGripper, that contains a palm and four bendable fingers as inspired by naturally evolved human hands, bird claws, and bacteriophages. Each NanoGripper finger consists of three phalanges connected by three rotatable joints that are bendable in response to the binding of other entities. NanoGripper functions are enabled and driven by the interactions between moieties attached to the fingers and their binding partners. We demonstrate that the NanoGripper can be engineered to effectively interact with and capture nanometer-scale objects, including gold nanoparticles, gold NanoUrchins, and SARS-CoV-2 virions. With multiple DNA aptamer nanoswitches programmed to generate a fluorescent signal that is enhanced on a photonic crystal platform, the NanoGripper functions as a highly sensitive biosensor that selectively detects intact SARS-CoV-2 virions in human saliva with a limit of detection of ~100 copies per milliliter, providing a sensitivity equal to that of reverse transcription quantitative polymerase chain reaction (RT-qPCR). Quantified by flow cytometry assays, we demonstrated that the NanoGripper-aptamer complex can effectively block viral entry into the host cells, suggesting its potential for inhibiting virus infections. The design, synthesis, and characterization of a sophisticated nanomachine that can be tailored for specific applications highlight a promising pathway toward feasible and efficient solutions to the detection and potential inhibition of virus infections. 

We present advanced biosensing methods with photonics crystal enhanced fluorescence emission from Quantum Dots, Plasmonic Fluorophores, and DNA Nano-grippers for nucleic acid, protein, and pathogen detection 

DNA-origami based nano-grippers, integrated with aptamer-based nanoswitches, generate fluorescent signals when detecting SARS-CoV-2. The integration of Photonic Crystal Enhanced Fluorescence Microscope enables a 104-fold enhancement compared to a single fluorophore reporter on glass substrate, providing a promising tool for ultrasensitive detection and rapid diagnostics. 

Plasmonic and photonic technologies have attracted strong interest in the past few decades toward several interdisciplinary applications stemming from unique light-matter interactions fostered by materials at the nanoscale. The versatility of plasmonic and photonic sensors for ultrasensitive, rapid, analyte sensing without extensive sample pre-treatment steps or sophisticated optics have resulted in their strong foothold in the broad arena of biosensing. Fluorescence-based bioanalytical techniques are widely used in liquid-biopsy diagnostics applications, but require many labeled target molecules to combine their emission output to achieve a practically useful signal-to-noise ratio. Approaches capable of amplifying fluorescence signals can provide signal-to-noise sufficient for digitally counting single emitters for ultrasensitive assays that are detected with simple and inexpensive instruments. [1]. Plasmonic and nano-photonics can function in synergy to amplify fluorescence signals. By concentrating optical energy well below the diffraction limit, plasmonic nanoantenna provide spatial control over excitation light, but their quality factor (Q) is modulated by radiative and dissipative losses. Photonic crystals (PC) as dielectric microcavities have a diffraction-limited optical mode volume despite being able to generate a high Q-factor. Here, we demonstrate a plasmonic-photonic hybrid system to produce a much stronger fluorescent enhancement for digital resolution biosensing. With an optimized dielectric spacer layer, around 200 Alexa-647 fluorophores have been coated over heterometallic Ag@Au core-shell plasmonic nanostructures with minimized Ohmic losses and quenching effects [2]. The target-specific molecule capture events enabled this plasmonic fluor to attach to the PC surface, forming a Plasmonic-Photonic hybrid mode. With much stronger local field enhancement, far-field directional emission, large Purcell enhancement, and high quantum efficiency, we report a two-orders signal enhancement from PC-enhanced plasmonic-fluor (104-fold brighter than a single fluorophore). This improved signal-to-noise ratio enabled us to perform single molecule imaging even with a 10x (NA=0.2) objective lens while offering 3 orders of magnitude boost in the limit of detection of Interleukine-6 (common biomarker for cancer, inflammation, sepsis, and autoimmune disease) compared with standard immunoassays in human plasma 

Abstract Assays utilizing fluorophores are common throughout life science research and diagnostics, although detection limits are generally limited by weak emission intensity, thus requiring many labeled target molecules to combine their output to achieve higher signal‐to‐noise. We describe how the synergistic coupling of plasmonic and photonic modes can significantly boost the emission from fluorophores. By optimally matching the resonant modes of a plasmonic fluor (PF) nanoparticle and a photonic crystal (PC) with the absorption and emission spectrum of the fluorescent dye, a 52‐fold improvement in signal intensity is observed, enabling individual PFs to be observed and digitally counted, where one PF tag represents one detected target molecule. The amplification can be attributed to the strong near‐field enhancement due to the cavity‐induced activation of the PF, PC band structure‐mediated improvement in collection efficiency, and increased rate of spontaneous emission. The applicability of the method by dose‐response characterization of a sandwich immunoassay for human interleukin‐6, a biomarker used to assist diagnosis of cancer, inflammation, sepsis, and autoimmune disease is demonstrated. A limit of detection of 10 fg mL⁻¹and 100 fg mL⁻¹in buffer and human plasma respectively, is achieved, representing a capability nearly three orders of magnitude lower than standard immunoassays.